Cariprazine Hydrochloride

卡利拉嗪盐酸盐

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameCariprazine Hydrochloride
Drug Alias NameCariprazine PR卡立哌嗪cariprazinum卡利拉嗪Cariprazine controlled-release +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor partial agonistsDopamine D3 receptor partial agonists +[6] 
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptorDopamine D2 receptor +[6] 
Therapy Area/IndicationsBipolar I DisorderSchizophreniaAutism Spectrum Disorder +[9] 
Global Approved IndicationsSchizophreniaBipolar Disorder
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/09/17
Country/TerritoryCzechiaBulgariaCanada +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGedeon RichterAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesGedeon RichterMapi Pharma LtdAllergan Plc +[10] 
Inactive CompaniesWhanin Pharmaceutical CompanyMitsubishi Tanabe Pharma CorpGedeon Richter Ltd +[8] 
Active IndicationsBipolar I DisorderSchizophreniaAutism Spectrum Disorder +[8] 
Inactive IndicationsAnxiety Disorders

Other Information

ATC CodeN05AX15
Related LinksWikipediaDrugBankKEGG